CA1083959A - Process for producing intravenous immune globulin - Google Patents
Process for producing intravenous immune globulinInfo
- Publication number
- CA1083959A CA1083959A CA291,764A CA291764A CA1083959A CA 1083959 A CA1083959 A CA 1083959A CA 291764 A CA291764 A CA 291764A CA 1083959 A CA1083959 A CA 1083959A
- Authority
- CA
- Canada
- Prior art keywords
- plasmin
- plasminogen
- immune globulin
- process according
- lysine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims abstract description 38
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 35
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 35
- 238000001990 intravenous administration Methods 0.000 title claims abstract description 9
- 102000013566 Plasminogen Human genes 0.000 claims abstract description 38
- 108010051456 Plasminogen Proteins 0.000 claims abstract description 38
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims abstract description 36
- 229940012957 plasmin Drugs 0.000 claims abstract description 34
- 239000004472 Lysine Substances 0.000 claims abstract description 22
- 229920000936 Agarose Polymers 0.000 claims abstract description 20
- 230000003171 anti-complementary effect Effects 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 18
- 235000019766 L-Lysine Nutrition 0.000 claims abstract description 14
- 210000004369 blood Anatomy 0.000 claims abstract description 7
- 239000008280 blood Substances 0.000 claims abstract description 7
- 238000005406 washing Methods 0.000 claims abstract description 5
- 239000002156 adsorbate Substances 0.000 claims abstract description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 238000011534 incubation Methods 0.000 claims description 11
- 239000003463 adsorbent Substances 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 239000000758 substrate Substances 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 5
- 239000000440 bentonite Substances 0.000 claims description 5
- 229910000278 bentonite Inorganic materials 0.000 claims description 5
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 4
- 230000002779 inactivation Effects 0.000 claims description 4
- 238000001179 sorption measurement Methods 0.000 claims description 4
- 238000013467 fragmentation Methods 0.000 claims description 3
- 238000006062 fragmentation reaction Methods 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 2
- 230000000415 inactivating effect Effects 0.000 claims description 2
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 238000005185 salting out Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 description 40
- 102000006395 Globulins Human genes 0.000 description 16
- 108010044091 Globulins Proteins 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 16
- 239000000499 gel Substances 0.000 description 16
- 229960003646 lysine Drugs 0.000 description 16
- 102000005686 Serum Globulins Human genes 0.000 description 15
- 108010045362 Serum Globulins Proteins 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
- 235000018977 lysine Nutrition 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 239000005018 casein Substances 0.000 description 7
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 7
- 235000021240 caseins Nutrition 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000011543 agarose gel Substances 0.000 description 4
- 239000007975 buffered saline Substances 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 108010044316 Cohn fraction III Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101000605403 Homo sapiens Plasminogen Proteins 0.000 description 2
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 2
- 201000005702 Pertussis Diseases 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007974 sodium acetate buffer Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- QWVCIORZLNBIIC-UHFFFAOYSA-N 2,3-dibromopropan-1-ol Chemical compound OCC(Br)CBr QWVCIORZLNBIIC-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 101001067249 Bos taurus Plasminogen Proteins 0.000 description 1
- 238000000665 Cohn process Methods 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000000963 caseinolytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- -1 for example Substances 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229910052901 montmorillonite Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
- Y10S530/831—Cohn fractions
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/744,906 US4075193A (en) | 1976-11-26 | 1976-11-26 | Process for producing intravenous immune globulin |
| US744,906 | 1976-11-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1083959A true CA1083959A (en) | 1980-08-19 |
Family
ID=24994418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA291,764A Expired CA1083959A (en) | 1976-11-26 | 1977-11-25 | Process for producing intravenous immune globulin |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4075193A (Direct) |
| JP (1) | JPS5369823A (Direct) |
| CA (1) | CA1083959A (Direct) |
| DE (1) | DE2752694A1 (Direct) |
| FR (1) | FR2372173B1 (Direct) |
| GB (1) | GB1552708A (Direct) |
| NL (1) | NL7713023A (Direct) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK139056B (da) * | 1976-04-06 | 1978-12-11 | Nordisk Insulinlab | Fremgangsmåde til udvinding af immunoglobulin, der er egnet til intravenøs indgivelse. |
| US4164495A (en) * | 1976-04-06 | 1979-08-14 | Nordisk Insulinlaboratorium | Method of recovering immunoglobulin using a polyol and an alkanoic acid |
| DE2658334C3 (de) * | 1976-12-23 | 1987-05-07 | Behringwerke Ag, 3550 Marburg | Verfahren zum Herstellen von Immunglobulinpräparationen mit verminderter Komplementaktivität und ein diese enthaltendes Arzneimittel |
| US4296027A (en) * | 1977-08-31 | 1981-10-20 | The Regents Of The University Of Minnesota | Pure intravenous human and animal gamma globulins |
| DE2846412A1 (de) * | 1978-10-25 | 1980-05-08 | Behringwerke Ag | Mittel zur behandlung allergischer reaktionen |
| JPS55124719A (en) * | 1979-03-22 | 1980-09-26 | Kowa Co | Preparation of immune globulin administrable by intravenous injection |
| US4272521A (en) * | 1979-07-16 | 1981-06-09 | Cutter Laboratories, Inc. | Purified immune serum globulin |
| DE2933015A1 (de) * | 1979-08-16 | 1981-03-26 | Behringwerke AG, 35041 Marburg | Verfahren zur herstellung der dritten komponente des komplements aus menschlichem blutplasma |
| JPH0662436B2 (ja) * | 1986-05-19 | 1994-08-17 | 株式会社ミドリ十字 | 静注用免疫グロブリン製剤の製造方法 |
| US5219578A (en) * | 1991-02-25 | 1993-06-15 | Innovet, Inc. | Composition and method for immunostimulation in mammals |
| US5211850A (en) * | 1991-07-26 | 1993-05-18 | Research Medical, Inc. | Plasma filter sorbent system for removal of components from blood |
| DE4344824C1 (de) * | 1993-12-28 | 1995-08-31 | Immuno Ag | Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung |
| EP0835880A1 (de) * | 1996-10-14 | 1998-04-15 | Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk | Verfahren zur Herstellung eines IgM Präparates für die intravenöse Applikation |
| US20020077276A1 (en) * | 1999-04-27 | 2002-06-20 | Fredeking Terry M. | Compositions and methods for treating hemorrhagic virus infections and other disorders |
| ATE442862T2 (de) * | 2000-10-12 | 2009-10-15 | Genentech Inc | Niederviskose konzentrierte proteinformulierungen |
| US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| US20100184132A1 (en) * | 2006-01-13 | 2010-07-22 | Secretary, Department Of Atomic Energy | Enzymatic Process for Debittering of Protein Hydrolysate Using Immobilized Peptidases |
| US20110123819A1 (en) * | 2007-12-21 | 2011-05-26 | Ge Healthcare Bio-Sciences Ab | Method for sterilization of chemically activated solid support materials |
| AR076640A1 (es) * | 2009-03-06 | 2011-06-29 | Genentech Inc | Formulacion con anticuerpo. metodo para estabilizar anticuerpo. articulo de manufactura |
| CA2976671C (en) | 2010-03-01 | 2021-01-12 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
| US20180305401A1 (en) * | 2015-10-21 | 2018-10-25 | Cambryn Biologics, Llc | Processes for purifying proteins from plasma |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3966906A (en) * | 1961-10-11 | 1976-06-29 | Behringwerke Aktiengesellschaft | Disaggregated gamma globulin and process for preparing it |
| US3449316A (en) * | 1967-03-03 | 1969-06-10 | American Cyanamid Co | Process for the purification of gamma globulin employing bentonite |
| US3808124A (en) * | 1972-04-14 | 1974-04-30 | American Cyanamid Co | Purification of human plasminogen |
| US3943245A (en) * | 1974-02-14 | 1976-03-09 | Armour Pharmaceutical Company | Purification of plasminogen |
-
1976
- 1976-11-26 US US05/744,906 patent/US4075193A/en not_active Expired - Lifetime
-
1977
- 1977-11-25 FR FR7735493A patent/FR2372173B1/fr not_active Expired
- 1977-11-25 DE DE19772752694 patent/DE2752694A1/de not_active Withdrawn
- 1977-11-25 GB GB49256/77A patent/GB1552708A/en not_active Expired
- 1977-11-25 JP JP14084577A patent/JPS5369823A/ja active Pending
- 1977-11-25 CA CA291,764A patent/CA1083959A/en not_active Expired
- 1977-11-25 NL NL7713023A patent/NL7713023A/xx not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5369823A (en) | 1978-06-21 |
| NL7713023A (nl) | 1978-05-30 |
| US4075193A (en) | 1978-02-21 |
| FR2372173A1 (Direct) | 1978-06-23 |
| DE2752694A1 (de) | 1978-06-01 |
| GB1552708A (en) | 1979-09-19 |
| FR2372173B1 (Direct) | 1981-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1083959A (en) | Process for producing intravenous immune globulin | |
| EP0083483B1 (en) | Ultrapurificated factor viii : c preparation | |
| USRE32011E (en) | Ultrapurification of factor VIII using monoclonal antibodies | |
| US5679776A (en) | Process for preparing a concentrate of blood coagulation factor VIII-von willebrand factor complex from total plasma | |
| EP0197901B1 (en) | Biologically active fragments of the human antihemophilic factor and method for their preparation and pharmaceutical preparations | |
| EP0140386B1 (en) | Method for the purification of lpf-ha | |
| US5252710A (en) | Process for manufacturing von Willebrand factor | |
| US5639857A (en) | Ultrapurification of factor IX and other vitamin k-dependent proteins | |
| Sadasivan et al. | Purification, properties, and immunological characterization of folate-binding proteins from human leukemia cells | |
| JPH0386900A (ja) | 新規なトロンビン結合性物質及びその製法 | |
| US5055557A (en) | Ultrapurification of factor IX and other vitamin K-dependent proteins | |
| CA1252744A (en) | Ultrapurification of factor ix and other vitamin k- dependent proteins | |
| US4065445A (en) | Pregnancy-specific β1 -glycoprotein and process for isolating it | |
| EP0253331B1 (en) | Thrombin-binding substance and process for its preparation | |
| US5760183A (en) | Process for the manufacture of very high-purity antithaemophilic factor (FVIIIC), and von Willebrand factor, and pharmaceutical compositions containing same | |
| US5445958A (en) | Process for purifying blood clotting factors | |
| Lee et al. | Purification of human erythrocyte transglutaminase by immunoaffinity chromatography | |
| JP3486196B2 (ja) | ストレプトリジンｏの精製方法、この方法により得られる完全ストレプトリジンｏおよびその使用 | |
| JPH09504532A (ja) | クロマトグラフィー法による第８因子を含むウィルス不活性化分画の製造方法 | |
| CZ211299A3 (cs) | Derivát von Willebrandova faktoru, zařízení tento derivát obsahující a způsob isolace proteinů | |
| WO1994009121A1 (en) | Preparation of enzyme for conversion of sub-type a and ab erythrocytes | |
| Madaras et al. | Isolation and insolubilisation of human F VIII by affinity chromatography | |
| Nagata et al. | Affinity chromatography of Streptomyces erythreus trypsin-like enzyme on Japanese quail ovomucoid | |
| EP0217061B1 (en) | Ultrapurification of factor VIII | |
| JPS6141548B2 (Direct) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |